Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

The artificial intelligence (AI) revolution is pushing up the overall stock market, but not every AI stock is performing well. Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are down by more than half from a peak they set this spring.The start-up drugmaker disappointed investors with lackluster results for its lead candidate in September. Luckily, it has a deep pipeline of less-advanced candidates that could allow its AI-powered platform to redeem itself.Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool